The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Mark, Kenneth M. K., Varn, Frederick S., Ung, Matthew H., Qian, Feng, Cheng, Chao
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414335/
https://ncbi.nlm.nih.gov/pubmed/28464832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3297-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados